Acquisition of JAK2, PTPN11, and RAS mutations during disease progression in primary myelodysplastic syndrome

Leukemia. 2006 Jun;20(6):1155-8. doi: 10.1038/sj.leu.2404190.

Authors

C-Y Chen, L-I Lin, J-L Tang, W Tsay, H-H Chang, Y-C Yeh, C-F Huang, R-J Chiou, M Yao, B-S Ko, Y-C Chen, K-H Lin, D-T Lin, H-F Tien

PMID: 16598312
DOI: 10.1038/sj.leu.2404190

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Aged
Aged, 80 and over
Child
Child, Preschool
Disease Progression
Female
Humans
Infant
Intracellular Signaling Peptides and Proteins / genetics*
Janus Kinase 2
Male
Middle Aged
Mutation
Myelodysplastic Syndromes / diagnosis
Myelodysplastic Syndromes / genetics*
Protein Tyrosine Phosphatase, Non-Receptor Type 11
Protein Tyrosine Phosphatases / genetics*
Protein-Tyrosine Kinases / genetics*
Proto-Oncogene Proteins / genetics*
Proto-Oncogene Proteins p21(ras) / genetics*
Risk Factors

Substances

Intracellular Signaling Peptides and Proteins
Proto-Oncogene Proteins
Protein-Tyrosine Kinases
JAK2 protein, human
Janus Kinase 2
PTPN11 protein, human
Protein Tyrosine Phosphatase, Non-Receptor Type 11
Protein Tyrosine Phosphatases
Proto-Oncogene Proteins p21(ras)